The drug is a generic version of Braintree's Miralax.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has announced that the US Food and Drug Administration has granted final approval for its ANDA (abbreviated new drug application) for Polyethylene Glycol 3350 NF for Oral Solution, 17 gram/scoopful.
The product is the AB-rated generic equivalent of Braintree's Miralax for Oral Solution, a product indicated for the treatment of occasional constipation.
According to Teva, total annual sales of Polyethylene Glycol 3350 NF for Oral Solution are approximately $153 million.
Published by Globes [online], Israel business news - www.globes.co.il - on May 8, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006